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Abstract
Background: The most remarkable feature of skeletal muscle is the capacity to adapt its morphological,
biochemical and molecular properties in response to several factors. Nonetheless, under pathological conditions,
skeletal muscle loses its adaptability, leading to atrophy or wasting. Several signals might function as
physiopathological triggers of muscle atrophy. However, the specific mechanisms underlying the atrophic
phenotype under different pathological conditions remain to be fully elucidated. In this paper, we address the
involvement of caspases in the induction of muscle atrophy in experimental models of amyotrophic lateral
sclerosis (ALS) expressing the mutant SOD1G93A transgene either locally or ubiquitously.
Results: We demonstrate that SOD1G93A-mediated muscle atrophy is independent from caspase activity. In
particular, the expression of SOD1G93A promotes a reduction of the phosphatidylinositol 3-kinase/Akt pathway
associated with activation of forkhead box O3. In contrast, the activation of caspases occurs later and is causally
linked to motor neuron degeneration, which is associated with exacerbation of the atrophic phenotype and a shift
in fiber-type composition.
Conclusion: This study suggests that muscle atrophy induced by the toxic effect of SOD1G93A is independent from
the activation of apoptotic markers and that caspase-mediated apoptosis is a process activated upon muscle
denervation.

Introduction
The decline in functional performance and restriction of
adaptability represents the hallmark of skeletal muscle
and brain pathologies. A crucial system severely affected
in several neuromuscular diseases is the loss of effective
connection between muscle and nerve, leading to a
pathological noncommunication between the two tissues.
Among degenerative diseases, amyotrophic lateral
sclerosis (ALS) represents one of the best examples in
which the interplay between muscle and nerve is
severely compromised [1,2]. The most typical feature of
this progressive lethal disease is the degeneration of
motoneurons, muscle weakness, fasciculations, muscle
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atrophy, speech and swallowing disabilities, progressive
paralysis and death caused by respiratory failure.
Although a significant proportion of familial ALS results
from a toxic gain of function associated with dominant
superoxide dismutase 1 (SOD1) mutations, the etiology
of the disease and its specific cellular origins have
remained difficult to define.
The best-known function of SOD1 is to detoxify cells
from accumulation of free radicals, which represent a
toxic by-product of mitochondrial oxidative phosphorylation [3]. The obvious loss of motor neurons in the spinal
cord initially focused attention on how mutant SOD1
may act within motor neurons to provoke neuronal
degeneration and death. However, the mutant gene products are expressed widely, raising the possibility that the
toxic cascade may be achieved wholly or in part by
mutant SOD1 action in non-neuronal cells. This notion
is supported by recent works. Notably, transgenic mice in
which mutant SOD1 was largely restricted to neurons
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developed disease only at an old age [4]. However, the
disease progressed slowly without reaching the same
degree of paralysis as the classical animal model of ALS,
in which the same mutant SOD1 gene is ubiquitously
expressed [5]. Although mutant SOD1 is also expressed
by muscle, it is not clear whether its presence in skeletal
muscle directly contributes to any pathological sign
of ALS.
This issue has been investigated recently by our group,
demonstrating that muscle selective expression of SOD1
mutation was sufficient to induce muscle atrophy associated with significant reduction in muscle strength, sarcomere disorganization and significant changes in
mitochondrial morphology [6]. These data, along with
other evidence [7-10], might explain how the ubiquitous
expression of SOD1 G93A first causes muscle atrophy,
which is later followed by alteration of the neuromuscular junction (NMJ), retrograde axonal degeneration and
last motor neuron death. This retrograde and progressive
(muscle to NMJ to nerve) sequential pattern of degeneration suggests the possibility that certain muscle abnormalities indeed precede motor neuron death rather than
result from it.
The characteristic loss in muscle mass, coupled with a
decrease in strength and force output, modulation in
brain metabolism and alteration in oxidative stress, has
been associated with a selective activation of apoptotic
pathways and a general reduction in survival mechanisms. Indeed, several studies have indicated the activation of apoptotic events in pathological conditions
associated with muscle atrophy, including neuromuscular diseases and muscle disuse [11]. However, whether
apoptosis is a trigger or a result of muscle atrophy in
ALS is an unanswered question.
The central component and the executor of the apoptotic machinery in several tissues is a proteolytic system
involving a family of cysteine proteases called caspases
[12]. Caspases are all expressed as inactive proenzymes
with a molecular weight between 50 and 33 kDa and are
activated after cleavage at the aspartate residues, generating the active product with lower molecular weight.
In this paper, we extend a previous study characterizing
the involvement of caspases in the induction of muscle
atrophy exerted by local and ubiquitous expression of the
SOD1G93A transgene. We reported that muscle atrophy in
myosin light chain (MLC)/SOD1G93A mice does not
involve the activation of caspase-1 and caspase-3, which
represent the initiator and final effector of cell death,
respectively. Of note, the expression and activity of caspase-1 and caspase-3 increased in the muscle of the classical animal models of ALS [5], which express the SOD1G93A
gene ubiquitously, but only at the paralysis stage.
In contrast, muscle atrophy in MLC/SOD1G93A mice
is the result of deregulation of the Akt pathway, which
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leads to a reduction in the activity of molecular markers
of protein synthesis, such as mammalian target of rapamycin (mTOR) and p70s6K, and to the activation of
proteolytic mechanisms mediated by forkhead box O3
(FoxO3) activity.

Results
Caspases are activated in muscle upon motor neuron
degeneration

We have determined the potential activation of apoptotic pathways in MLC/SOD1G93A transgenic mice. Critical players in apoptosis-mediated muscle atrophy are
caspases (cysteine-dependent, aspartate-directed proteases). In particular, caspase-3 is a critical executioner
of apoptosis; it is translated as an inactive 37-kDa
proenzyme that is activated after cleavage, generating a
low-molecular-weight active product (p17/p19) [13].
Western blot analysis for the total and the cleaved
form of caspase-3 expression (Figure 1A) performed on
16-week-old wild-type and MLC/SOD1 G93A skeletal
muscle did not reveal a significant difference between
the two experimental models, suggesting that at this
stage, apoptosis does not play a critical and pivotal role
in the induction of muscle atrophy mediated by reactive
oxygen species accumulation. It has been reported that
expression of apoptosis-related proteins increases in
denervated muscle atrophy [10,14-16], raising the prospect that apoptosis is not a mechanism necessarily
involved in the induction of muscle atrophy, but rather
might be a later event associated with denervation.
To support this hypothesis, we analyzed and compared
caspase expression and activity in the muscles of both
MLC/SOD1G93A [6] and SOD1G93A mice [5] at 123 days
of age. Of note, the SOD1G93A mouse represents the classical animal model of ALS; it does not display any pathological sign of the disease until age 111 ± 1.8 days, which
is considered the disease onset [5,17], whereas motor
neuronal degeneration and complete muscle paralysis
occurs at age 123 days [5,17]. As shown in Figure 1A, the
cleaved active product of caspase-3 selectively increased
in the paralyzed SOD1G93A muscle.
To further verify the involvement of caspases on muscle
wasting associated with motor neuron degeneration, we
evaluated the activity of caspase-1 and caspase-3 in wildtype, MLC/SOD1G93A and SOD1G93A muscles. Figures 1B
and 1C show that the activity of caspase-1 and caspase-3
increased in SOD1G93A mice at 123 days of age, which
corresponds to the stage of motor neuron degeneration
and paralysis. In contrast, in younger presymptomatic
SOD1G93A mice (age 90 days), caspase-1 and caspase-3
activity did not show significant differences compared to
wild-type and MLC/SOD1G93A mice (data not shown).
These data suggest that muscle atrophy associated with
either local or ubiquitous expression of the toxic
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Figure 1 Caspase expression and activity are selectively upregulated in atrophic muscle of SOD1 G93A mice at paralysis stage.
(A) Representative Western blot analysis using caspase-3 antibody (top) and cleaved caspase-3 antibody (bottom) in wild-type (WT) (lane 1),
myosin light chain (MLC)/SOD1G93A (lane 2) and SOD1G93A (lane 4) transgenic muscle. Cnt+ represents the positive control (HeLa cells treated
with staurosporin) for cleaved caspase-3. Immunoblotting for a-tubulin served as a control for protein loading. (B and C) Analysis (n = 5) of (B)
caspase-1 and (C)caspase-3 activity on WT, MLC/SOD1G93A and SOD1G93A transgenic mice. *P < 0.05. Mean values ± SEM for caspase-1: WT =
1.055 ± 0.03, MLC/SOD1G93A = 0.908 ± 0.10 and SOD1G93A = 2.385 ± 0.10. Mean values ± SEM for caspase-3: WT = 1.01 ± 0.01, MLC/SOD1G93A =
0.75 ± 0.18 and SOD1G93A = 1.56 ± 0.07.

SOD1G93A protein is independent of caspase activation,
whereas caspase-mediated apoptosis was greater in paralyzed muscle.
Muscle atrophy is independent from motor neuron
degeneration

The evidence that caspase activity increases upon muscle denervation and that local expression of SOD1G93A
did not induce significant changes in the number of
motor neurons [6], suggests that muscle atrophy associated with muscle expression of SOD1G93A is causally
linked to the direct toxic effect of mutant SOD1 protein
rather than to muscle denervation.
To support this evidence, we analyzed relevant markers of nerve activity. In particular, nerve activity has a
major role in the maintenance and modulation of fibertype properties by selective activation of fiber-specific
gene expression [18]. A shift in fiber composition therefore constitutes a marker associated with muscle denervation [18]. Specifically, motor neuron degeneration and

muscle denervation cause a shift from slow to fast muscle phenotype.
Immunohistochemical analysis (Figure 2A) for the
expression of myosin heavy chain-slow (MyHC-slow)
revealed that fiber-type composition was unchanged in
the soleus muscle of both wild-type and MLC/
SOD1G93A mice. In contrast, fiber-type composition was
altered in both denervated wild-type soleus muscle and
SOD1G93A soleus muscles at paralysis stage, with a shift
toward a fast fiber type (Figure 2A).
Notably, the denervated muscles of wild-type mice and
the paralyzed muscle of SOD1G93A mice displayed a more
severe atrophic phenotype, as indicated by the reduction
in fiber diameter (Figure 2A). This suggests that motor
neuron degeneration, activating the caspase-mediated
proteolytic system, exacerbates the atrophic phenotype.
Other factors whose expression and activity are
mediated by innervation and are also associated with
muscle denervation in ALS are neurite outgrowth inhibitor (Nogo)-A, Nogo-C and the nicotinic acetylcholine
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Figure 2 Muscle atrophy is exacerbated in denervated mice. (A) Immunofluorescence analysis of myosin heavy chain (MyHC)-slow (green)
and laminin (red) performed on soleus muscles of WT, MLC/SOD1G93A, WT-denervated and SOD1G93A muscle at age 123 days, which
corresponded to the paralysis stage in SOD1G93A mice. Bar, 50 μm. (B) Real-time polymerase chain reaction (PCR) for nicotinic acetylcholine
receptor (AChR)-g expression in both WT and MLC/SOD1G93A transgenic muscle. **P = 0.006. (C) Representative Western blot analysis (left) for
glial fibrillary acidic protein (GFAP) expression in the spinal cord of WT, MLC/SOD1G93A and SOD1G93A transgenic mice at 123 days old.
Immunoblotting for b-actin served as a control for protein loading. Right: Densitometric analysis of seven separate immunoblot experiments
showing the expression levels of GFAP calculated as ratios of GFAP/b-actin expression. **P < 0.005.

receptor (AChR) [19,20]. Nogo-A and Nogo-C expression, occurring early in ALS skeletal muscle, could
cause repulsion and destabilization of the motor nerve
terminals and subsequent degeneration of the axons and
motor neurons. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis (data not shown)
did not reveal significant changes in Nogo-A and NogoC expression between wild-type and MLC/SOD1 G93A
transgenic mice.
The AChR subunit mRNA accumulation and maintenance is also mediated by neural factors. It has been
demonstrated that the g-subunit mRNA level is tightly
coupled to innervation. It is undetectable or low in
innervated, normally active muscle and in innervated
but disused muscle, whereas it is abundant along the
whole fiber length in denervated muscle or in muscle in
which the neuromuscular contact is intact but the
release of transmitters is blocked [20]. Real-time PCR

analysis for AChR-g expression (Figure 2B) showed a
slight but not significant increase in MLC/SOD1 G93A
transgenic mice compared to wild type. Notably, the
levels of AChR-g expression were significantly and conspicuously upregulated in the SOD1 G93A muscle at
paralysis stage (Figure 2B).
In addition, astrocyte activity, which is concomitant
with motor neuron degeneration and normally increases
at later stages of ALS disease [21,22], did not change
between wild-type and MLC/SOD1 G93A spinal cord,
while it selectively increased in the SOD1G93A spinal cord
at later stages of the disease as revealed by glial fibrillary
acidic protein (GFAP) expression (Figure 2C). It seems
likely that muscle atrophy is primarily associated with
events related to the toxic effects of SOD1G93A mutant
protein, whereas motor neuron degeneration is a later
event that contributes to exacerbation of the atrophic
phenotype, promoting paralysis and muscle wasting.
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Analysis of molecular pathways involved in SOD1G93Ainduced muscle atrophy

Transcriptional upregulation or downregulation of atrophy-related genes is a characteristic feature of muscle
atrophy [23]. Several triggers and signaling proteins
have been postulated as regulators of muscle atrophy,
and it is often not clear whether muscle atrophy is the
result of a reduction in protein synthesis, an increase in
protein degradation or the combination of the two. Akt
represents the critical signaling involved in protein
synthesis and muscle hypertrophy [23]. Under different
pathological conditions, Akt is dephosphorylated and its
activity is reduced below control levels, leading to activation of atrophic pathways [24]. We analyzed the Akt
expression, activity and cascade in both 16-week-old
wild-type and MLC/SOD1G93A mice.
Figure 3A shows that the absolute ratio of pAkt to
Akt protein was significantly reduced in MLC/
SOD1G93A transgenic muscle compared with wild type.
A downstream effector of the Akt pathway is the mTOR
kinase, which in turn promotes the phosphorylation of
p70S6K, leading to an increase in protein synthesis.
Western blot analysis revealed significant downregulation of the phosphorylation levels of both mTOR and
p70S6K intermediate in MLC/SOD1 G93A transgenic
muscle, compared with that of wild-type littermates
(Figures 3B and 3C).
In several atrophic conditions, the inhibition of the
Akt pathway also leads to the activation of the FoxO
members, which are able to promote muscle atrophy
when overexpressed in cells and in whole muscle [24].
Western blot analysis (Figures 3D and 3E) revealed a
selective accumulation of the dephosphorylated form of
FoxO3, but not of FoxO1, in MLC/SOD1G93A transgenic
muscles compared to those of wild-type mice.
These data suggest that muscle atrophy induced by
local SOD1G93A expression is the result of the deregulation of the Akt pathway. This leads to two distinct
responses: (1) an inhibitory effect on translation via the
inhibition of mTOR and the dephosphorylation of
p70S6K and (2) the activation of the FoxO3 pathway.

Conclusions
The present work provides new insights concerning the
control of muscle fiber size and the mechanisms of atrophy in animal models of ALS. Motor neuron degeneration and muscle atrophy are the major pathological
processes associated with ALS, suggesting that nerve
activity plays an important role in muscle homeostasis
and remodeling. However, whether muscle atrophy associated with ALS is independent from motor neuron
degeneration or results from it remains to be defined.
We recently generated a novel transgenic mouse model
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in which the mutant SOD1 G93A gene involved in a
familial form of ALS was selectively expressed in skeletal
muscle [6]. We demonstrated that local expression of
SOD1 G93A was sufficient to promote muscle atrophy
and to impair the functional performance of skeletal
muscle [6].
In the present study, we have extended previous work
with the aim of defining the potential signal transduction pathways activated in response to SOD1 G93A ,
expressed either locally [6] or ubiquitously [5], that
cause muscle atrophy. In particular, in this study we
have demonstrated that muscle atrophy in SOD1G93A
mice is an early event that is independent from motoneuron degeneration. The mechanisms responsible for
the promotion of muscle atrophy involve a deregulation
of Akt pathways and the activation of FoxO pathways,
whereas caspases are selectively activated upon denervation or motoneuron degeneration.
The results in this study are consistent with a model
(Figure 4) whereby muscle atrophy is an early pathological event that does not involve the expression and activity of caspases. In particular, the expression of
SOD1G93A promotes a reduction of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, leading to a reduction in protein synthesis and activation of the FoxO
transcription factor. The two molecular branches of Akt
activity might in tandem promote muscle atrophy at the
early stage of ALS disease.
This initial morphofunctional alteration of skeletal
muscle might be followed by NMJ destruction, distal
axonopathy, astrocytosis in the spinal cord and finally
motor neuron loss. This leads to a late exacerbation of
muscle atrophy caused by caspase activation. Further
work will define whether and how skeletal muscle
affects the nervous system.

Methods
Mice

SOD1 G93A transgenic mice (Jackson Laboratory,
Bar Harbor, ME, USA) express the human mutant
SOD1 G93A allele containing the Gly93RAla (G93A)
substitution, which is driven by its endogenous human
promoter [5]. MLC/SOD1G93A mice express the human
mutant SOD1G93A transgene under the transcriptional
control of muscle-specific promoter (MLC), and its
expression is selectively restricted in skeletal muscle.
The animals were housed in a temperature-controlled
(22°C) room with a 12:12 hour light-dark cycle. All
procedures involving the use of animals were performed following experimental protocols approved by
the Italian Ministry of Health (ISS) according to dlgs.
116/92 of European Economic Community Directive
609/86.
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Figure 3 Local expression of SOD1G93A induces muscle atrophy via the negative modulation of the Akt pathway. (A-C) Immunoblot
analysis (n = 5) of total Akt and the phosphorylated form of Akt, mammalian target of rapamycin (mTOR) and p70S6K proteins in muscles of 4month-old control (WT) and MLC/SOD1G93A mice. (A) Akt phosphorylation (pAkt) was significantly reduced in MLC/SOD1G93A muscle, with a
slight change in total Akt levels compared to WT muscle. Right: Densitometric analysis of the ratio between total Akt and the phosphorylated
form of Akt. (B and C) The phosphorylation levels of the downstream Akt intermediates, (B) mTOR and (C) p70S6K, resulted in significant
downmodulation in the muscle of MLC/SOD1G93A mice. Right: Densitometric analysis of five separate immunoblot experiments showing the ratio
between total and phosphorylated forms of (B) mTOR and (C) p70S6K expression. (D and E) Representative Western blot analysis of (D) forkhead
box O1 (FoxO1) (n = 5) and (E) FoxO3 (n = 3) expression in muscles of both WT and MLC/SOD1G93A transgenic mice. Right: Densitometric
analysis for FoxO1 and FoxO3 expression. Immunoblotting for a-tubulin served as a control for protein loading. *P < 0.05. Mean values ± SEM
for pAkt/Akt: WT = 1.48 ± 0.14 and MLC/SOD1G93A = 0.66 ± 0.12. Mean values ± SEM for pmTOR/mTOR: WT = 5.21 ± 0.88 and MLC/SOD1G93A =
2.65 ± 0.73. Mean values ± SEM for p-p70/p70: WT = 1.21 ± 0.12 and MLC/SOD1G93A = 0.64 ± 0.08. Mean values ± SEM for FoxO1: WT = 0.35 ±
0.01 and MLC/SOD1G93A = 0.35 ± 0.15. Mean values ± SEM for FoxO3: WT = 0.37 ± 0.19 and MLC/SOD1G93A = 1 ± 0.47.
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Figure 4 A summary of the signal transduction pathways activated in SOD1G93A transgenic mice. The toxic effects of SOD1G93A induce a
local accumulation of reactive oxygen species which affects the Akt pathways, promoting muscle atrophy. The later motor neuron degeneration
leads to more severe muscle atrophy and to a shift in fiber-type composition (see text of the results section for details).

Protein extraction and Western blot analysis

Immunofluorescence analysis

Protein extraction was performed in lysis buffer (50 mM
Tris HCl, pH 7.4, 1% wt/vol Triton X-100, 0.25%
sodium deoxycholate, 150 mM sodium chloride, 1 mM
phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/
ml leupeptin, 1 mg/ml pepstatin, 1 mM sodium orthovanadate and 1 mM sodium fluoride). Equal amounts of
proteins (100 μg) from each muscle lysate were separated in sodium dodecyl sulfate polyacrylamide gel and
transferred onto a Hybond-C Extra nitrocellulose membrane (GE Healthcare Life Sciences, Little Chalfont,
Buckinghamshire, UK). After blocking with 5% nonfat
dry milk, membranes were blotted with antibodies
against caspase-3, Akt, pAkt, P70s6K, pP70s6K, FoxO1,
FoxO3 (Cell Signaling Technology, Danvers, MA, USA),
GFAP (Dako, Glostrup, Denmark) and tubulin (Sigma,
St. Louis, MO, USA). The membranes were washed in
Tris-buffered saline and Tween 20 (TBS-T) and incubated with horseradish peroxidase secondary antibody
(diluted 1:10,000 in TBS-T) for 1 hour. Protein detection was carried out with SuperSignal Chemiluminescent
Substrate (Pierce Biotechnology, Rockford, IL, USA).

For immunofluorescence analysis, 7-μm-thick muscle
cryosections were fixed with 4% paraformaldehyde,
washed in phosphate-buffered saline with 1% bovine
serum albumin and 0.2% Triton X-100, preincubated for
1 hour in 10% goat serum at room temperature and
incubated overnight at 4°C with primary antibodies
MyHC-slow and laminin (Sigma).

Caspase activity

Caspase activity was evaluated with the caspase-1 and caspase-3/ICE Colorimetric Protease Assay Kit (MBL International, Woburn, MA, USA). The assay is based on
spectrophotometric detection of the chromophore pnitroanilide (pNA) after cleavage from the labeled substrate YVAD-pNA. Protein extracts from wild-type,
SOD1G93A and MLC/SOD1G93A mice were incubated with
YVAD-pNA substrate at 37°C for 2 hours. The pNA emission was quantified with a spectrophotometer at 400 nm.

RNA extraction and quantitative reverse transcription
polymerase chain reaction

Total RNA was prepared from liquid nitrogen powdered
tissues homogenized in TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). Total RNA (1 μg) was treated with
DNase I, Amplification Grade (Invitrogen, Carlsbad, CA,
USA), and reverse-transcribed using the SuperScript™
III reverse transcriptase (Invitrogen, Carlsbad, CA,
USA). Quantitative PCR was performed using ABI
Prism 7000 Sequence Detection System software
(Applied Biosystems, Carlsbad, CA, USA), and TaqMan® Universal Master Mix (Applied Biosystems, Carlsbad, CA, USA) for real-time RT-PCR amplification.
Quantitative RT-PCR sample values were normalized for
the expression of b-actin and reported as arbitrary units.
Statistical analysis

The Mann-Whitney U test was used for comparison
among the different experimental models.
Abbreviations
AChR: nicotinic acetylcholine receptor; ALS: amyotrophic lateral sclerosis;
GFAP: glial fibrillary acidic protein; MyHC: myosin heavy chain; NMJ:
neuromuscular junction; SOD1: superoxide dismutase 1; WT: wild type.
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